Alliance Wealth Advisors LLC UT Sells 8,086 Shares of Abbott Laboratories $ABT

Alliance Wealth Advisors LLC UT trimmed its position in Abbott Laboratories (NYSE:ABT) by 30.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,225 shares of the healthcare product maker’s stock after selling 8,086 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Abbott Laboratories were worth $2,441,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Vanguard Group Inc. boosted its stake in shares of Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares during the period. State Street Corp lifted its holdings in Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after purchasing an additional 689,517 shares during the last quarter. Geode Capital Management LLC boosted its position in Abbott Laboratories by 3.8% during the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after purchasing an additional 1,390,554 shares during the period. Norges Bank acquired a new position in shares of Abbott Laboratories in the second quarter valued at $3,026,180,000. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Abbott Laboratories by 5.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after buying an additional 821,325 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Exact Sciences stockholders approved Abbott’s acquisition proposal (preliminary results showed >99% of votes cast and ~67% of outstanding shares represented), clearing a key shareholder hurdle and advancing Abbott’s expansion into cancer screening/diagnostics — a strategic deal that should broaden revenue mix and long-term growth prospects. Exact Sciences Stockholders Approve Acquisition by Abbott
• Positive Sentiment: Abbott’s board declared its 409th consecutive quarterly dividend at $0.63/share, reinforcing a reliable income profile that supports shareholder confidence and may attract income-oriented investors. Abbott declares 409th consecutive quarterly dividend
• Positive Sentiment: Abbott reported positive clinical results for its Amulet 360 Left Atrial Appendage (LAA) occluder presented at the AF Symposium — a favorable outcome for the company’s structural-heart/device pipeline that could support future market adoption and revenue growth in electrophysiology/cardiology. Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
• Neutral Sentiment: Abbott’s board approved governance changes to streamline the board (smaller board size). This is a modest corporate-governance move that could slightly improve oversight/efficiency but is unlikely to drive material near-term earnings changes. Abbott Laboratories Streamlines Governance With Smaller Board
• Neutral Sentiment: Media comparisons (BSX vs ABT) highlight Abbott’s valuation appeal, CGM momentum and strategic deals as advantages vs. Boston Scientific — useful context for investors but not a direct corporate action. BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
• Negative Sentiment: BTIG cut its price target for ABT to $140, which may temper near-term analyst-driven upside and investor enthusiasm despite the company’s strategic wins; analyst revisions can influence sentiment and trading volume. BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Barclays lowered their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Oppenheimer reduced their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Raymond James Financial lowered their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, BTIG Research dropped their target price on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Stock Up 0.0%

NYSE ABT opened at $112.21 on Friday. The business has a fifty day moving average price of $118.46 and a two-hundred day moving average price of $125.84. The stock has a market capitalization of $195.11 billion, a PE ratio of 30.16, a PEG ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the firm earned $1.34 EPS. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.